Gadavist Imaging Bulk Package Approved for Multi-Patient Dosing
Gadavist® Imaging Bulk Package is supplied as 604.72mg/mL of gadobutrol in 30mL and 65mL multidose containers.
Gadavist® Imaging Bulk Package is supplied as 604.72mg/mL of gadobutrol in 30mL and 65mL multidose containers.
The Food and Drug Administration (FDA) has approved Lumason (sulfur hexafluoride lipid-type A microspheres; Bracco Diagnostics Inc.), an ultrasound enhancing agent, for use in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in pediatric patients with suboptimal echocardiograms. Previously, the treatment was only approved for…
Exposure often occurs early in the pregnancy, likely before pregnancy has been recognized
The Food and Drug Administration (FDA) has approved Varibar Thin Liquid for oral suspension (barium sulfate; Bracco Diagnostics Inc.) for use in modified barium swallow (MBS) examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. Varibar Thin Liquid is a radiographic contrast agent that is supplied as a powder…
The Food and Drug Administration (FDA) has approved Gadavist (gadobutrol; Bayer) injection for use in cardiac magnetic resonance imaging (MRI) to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). The approval was based on data from two phase 3 multicenter, open-label trials that…
The uEXPLORER combines positron emission tomography (PET) with X-ray computed tomography (CT) allowing for imaging of the entire body at the same time.
An artificial intelligence system can diagnose and classify intracranial hemorrhage (ICH).
Healthy volunteers, patients with chronic back pain, and runners did not have deep bone marrow edema lesions, but 89.4% of axial SpA patients and 14.3% of women with postpartum back pain did have lesions.
The researchers found that 72.8% of children had negative CXRs, with 8.9% of these children clinically diagnosed with pneumonia and 9.3% given antibiotics for other bacterial syndromes.
The integrated risk prediction model combining smoking exposure with the biomarker score yielded an area under the curve of 0.83 versus 0.73 for a model based on smoking exposure alone.